Investing in the future of medicine


Bringing science to patients:

We have helped bring
37 products to market.

Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients.

Together, let’s chart a path to get your ideas there faster.

Exceptional people & impactful products

Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.

We are
stage agnostic

At Omega Funds, we understand luck is not random but favors the prepared mind.

Our people have the experience, commitment and connections to help entrepreneurs and founders increase their odds of success.

Management Team
  • Richard Lim

    Richard joined Omega Funds in 2008. His career spans 25 years in private equity investing and strategic consulting, all within life science and healthcare. At Omega, he is a member of the firm’s investment committee and acts as President of Omega Fund Management LLC; his primary investment focus is in drug discovery and development companies, and is actively involved in the firm’s secondary buyout practice and investments in academic spinouts.

    Previously, Richard was a General Partner at MVM Life Science Partners, a life science-focused venture capital firm, where he founded the firm’s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), where he specialized in healthcare growth capital and leveraged buyout transactions. Prior to SKM, now known as Apax Partners Inc., Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than three dozen small and large biotechnology firms. He was also an Associate with the M&A investment bank BT Wolfensohn. He has served on a number of boards of biotechnology, specialty pharmaceutical, and medical device companies. He serves on the advisory boards of the Deshpande Center at the Massachusetts Institute of Technology. Richard earned his AB and MBA degrees from Harvard University.

  • Claudio Nessi

    Claudio joined Omega Funds in 2016. In addition to managing NeoMed’s funds, Claudio assists with and advises on new investments for Omega and sits on the investment committee.

    Claudio joined NeoMed in 2001 and became a Partner in 2004. He has over 15 years’ experience of venture capital investing in healthcare in Europe and the US. Prior to NeoMed, Claudio was a Venture Partner with Genevest Consulting Group SA, Geneva. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut. Claudio has an MBA from Erasmus University, the Netherlands and a PhD degree in Genetics from the University of Pavia, Italy.

  • Anne-Mari Paster

    Anne-Mari joined Omega Funds in 2009 after 17 years in healthcare venture capital finance. At Omega, Anne-Mari is a member of the Investment Committee and is responsible for overseeing the firm’s financial and administrative operations.

    Previously, she was a Partner and Chief Financial Officer at Third Rock Ventures (TRV), a venture firm focused on life sciences investing. She joined TRV to establish its operations and assisted the firm in successfully raising its inaugural fund in 2007. She managed all fund, company and portfolio operations as well as investor relations. Prior to TRV, Anne-Mari served as CFO of MPM Capital, a leading biotech venture capital firm with 4 funds and over $2.3 billion under management. During her 14-year tenure with MPM, she was responsible for financial management of MPM’s venture funds and other entities, financial reporting, building and oversight of all back office operations, investor relations and office administration. She was also a Founder and CFO of APS Material Services. Anne-Mari received her BS in Engineering at the Turku Institute of Technology in Finland and has completed advanced studies in corporate finance at Boston University.

  • Otello Stampacchia

    Otello founded Omega Funds in 2004 and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of Omega’s therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders.

    Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.